Objective: This study sought to determine if doxycyline and minocycline released from PLGA NS inhibit MMP activity of human gingival fibroblasts (hGFs) in a controlled-release manner.
Method: Doxycycline- and minocycline-containing PLGA NS were fabricated using a modified water-in-oil-in-oil emulsion method. Doxycline inhibition of commercial MMP9 was evaluated using gelatin zymography. To test MMP inhibition of NS-released tetracyclines, doxycline NS in PBS were incubated at 37°C. At days 1, 3, 5, 7, 10, and 14, NS/PBS were centrifuged, supernatant was incubated in hGF cell culture overnight then evaluated using gelatin zymography. This process was repeated using minocycline.
Result: Zymography indicated doxycycline inhibited MMP9 in a dose-dependent manner with a 100 ug dose as optimal. NS-released minocycline had inhibitory effects on hGF MMPs at each evaluation point compared with control groups. NS-released doxycycline had inhibitory effects on human gingival fibroblast MMPs compared with no treatment.
Conclusion: Doxycycline demonstrates dose-dependent MMP9 inhibition. Minocycline released from NS demonstrated greater MMP inhibition versus control; thus, NS encapsulation of tetracyclines preserves some MMP-inhibitory activity. This drug delivery system offers potential for antimicrobial and anti-MMP activities for tissue engineering applications.
Keywords: Antimicrobials, Biomaterials, Periodontal disease and Regeneration
See more of: Periodontal Research - Therapy